$82.67
2.212.75%
Últ. Act.: Nov 3, 11:49 AM
Corcept Therapeutics (CORT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Corcept Therapeutics (CORT) publicó su última previsión de julio 29, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $1.1B - $1.2B para el período.
En comparación con la previsión anterior, Corcept Therapeutics elevado redujo su previsión de ingresos desde un rango anterior de $950M - $1.05B.
Corcept Therapeutics ha emitido 19 actualizaciones de orientación entre el noviembre 3, 2022 y el julio 29, 2026. During this period, the company raised its outlook 13 times and lowered it 3 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.81 | $0.02 | $-0.17 | $0.31 |
| Actual | — | $0.36 | $-0.30 | $0.20 |
| Surprise | — | +1700.0% | -76.5% | -35.5% |
| Revenue | ||||
| Estimate | $334.9M | $219.3M | $183.8M | $254.7M |
| Actual | — | $256.1M | $164.9M | $202.1M |
| Surprise | — | +16.8% | -10.3% | -20.6% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $1.13 | $0.43 | $0.78 |
| Revenue | |||
| Consensus | $389.9M | — | — |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 29, 2026 | $0.36 | $0.02 | 1700.0 % |
| Q1 | Apr 30, 2026 | $-0.30 | $-0.17 | -76.5 % |
| Q4 | Feb 24, 2026 | $0.20 | $0.31 | -35.5 % |
| Q3 | Nov 4, 2025 | $0.16 | $0.15 | 6.67 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q2 | Jul 29, 2026 | $256.15M | $219.32M | 16.8 % |
| Q1 | Apr 30, 2026 | $164.90M | $183.78M | -10.3 % |
| Q4 | Feb 24, 2026 | $202.13M | $254.72M | -20.6 % |
| Q3 | Nov 4, 2025 | $207.64M | $218.79M | -5.10 % |